Akili (AKLI, $1.03) gets Equal Weight rating from Morgan Stanley
Morgan Stanley initiated coverage on Akili Inc. with a rating of Equal Weight and a price target of $2 on the stock.
According to the analyst, the digital medicine company’s product EndeavorRx could generate more than $200 million in peak sales in ADHD. EndeavorRx got marketing authorization from the FDA in mid-2020 as a medical device for patients aged 8-12 with ADHD, and a commercial launch began in late 2022.
The analyst indicated that given the apparent skepticism of the market for digital therapeutics’ sales potential, a significant focus on early launch metrics such as script growth and refill rates is expected.
Akili’s pivotal data in ADHD patients aged 13-17 and 18+ is likely in the second half of 2023.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Advertisement
General Information
Industry PackagedSoftware
Advertisement